Aurinia Pharmaceuticals Inc (AUPH) — closed signal from March 31, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 29, 2026.
Predicted vs. what happened
AUPH price · publication thesis → realized outcomesplit-adjusted
$13.80 – $14.90Entry zone — fair-value band
$14.55Published — price the day we called it
$16.00Target — the price the thesis aimed for
$19.25Peak — highest point inside the window, not a realized return
$16.79Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 6 days.
Peak price
$19.25
peak on June 24, 2026 — not a realized returnPeak gain
+32.3%
peak, from the publication priceWindow close
$16.79
end-of-window price, context onlyDays to target
6
Window
March 31, 2026 – June 29, 2026
The thesis — published March 31, 2026
Predicted growth
+10%
over the measurement windowTarget price
$16.00
the price the thesis aimed forEntry zone
$13.80 – $14.90
the fair-value band we waited forPrice at publication
$14.55
published March 31, 2026Confidence
63%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Aurinia looks like a short-term special situation: a recent acquisition and management change could lift expectations, but much depends on the deal going smoothly and investors trusting management choices. Trading is light, so the stock can move sharply. Cash and a low valuation give some cushion, but overall confidence is limited.
Primary drivers
- The Kezar deal creates a clear near-term event that could change sentiment
- New management can change expectations about strategy and spending
- A strong cash position and low valuation help limit downside
- Thin trading and deal execution risk make the setup less reliable
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.